[1] |
Reichler MR, Khan A, Sterling TR, et al. Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis. J Infect Dis, 2018,218(6):1000-1008. doi: 10.1093/infdis/jiy265.
doi: 10.1093/infdis/jiy265
URL
pmid: 29767733
|
[2] |
Park SY, Han S, Kim YM, et al. Risk of active tuberculosis development in contacts exposed to infectious tuberculosis in congregate settings in Korea. Sci Rep, 2020,10(1):1306. doi: 10.1038/s41598-020-57697-1.
URL
pmid: 31992740
|
[3] |
Stagg HR, Zenner D, Harris RJ, et al. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med, 2014,161(6):419-428. doi: 10.7326/M14-1019.
doi: 10.7326/M14-1019
URL
pmid: 25111745
|
[4] |
Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep, 2020,69(1):1-11. doi: 10.15585/mmwr.rr6901a1.
doi: 10.15585/mmwr.rr6901a1
URL
pmid: 32053584
|
[5] |
U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common terminology criteria for adverse events (CTCAE) version 4.0. 2010-06-14.
|
[6] |
孙振球. 医学统计学.3版. 北京: 人民卫生出版社, 2010.
|
[7] |
Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011,365(23):2155-2166. doi: 10.1056/NEJMoa1104875.
URL
pmid: 22150035
|
[8] |
Huang YW, Yang SF, Yeh YP, et al. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Medicine (Baltimore), 2016,95(34):e4126. doi: 10.1097/MD.0000000000004126.
|
[9] |
Schmit KM, Lobato MN, Lang SG, et al. High Completion Rate for 12 Weekly Doses of Isoniazid and Rifapentine as Treatment for Latent Mycobacterium tuberculosis Infection in the Federal Bureau of Prisons. J Public Health Manag Pract, 2019,25(2):E1-E6. doi: 10.1097/PHH.0000000000000822.
doi: 10.1097/PHH.0000000000000822
URL
pmid: 30024493
|
[10] |
Villa S, Ferrarese M, Sotgiu G, et al. Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy. J Clin Med, 2019,9(1):101. doi: 10.3390/jcm9010101.
|
[11] |
Onwubiko U, Wall K, Sales RM, et al. Using Directly Observed Therapy (DOT) for latent tuberculosis treatment-A hit or a miss? A propensity score analysis of treatment completion among 274 homeless adults in Fulton County, GA. PLoS One, 2019,14(6):e0218373. doi: 10.1371/journal.pone.0218373.
URL
pmid: 31226132
|
[12] |
Lam CK, McGinnis Pilote K, Haque A, et al. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study. J Med Internet Res, 2018,20(11):e287. doi: 10.2196/jmir.9825.
doi: 10.2196/jmir.9825
URL
pmid: 30459146
|
[13] |
Hirsch-Moverman Y, Colson PW, Bethel J, et al. Can a peer-based intervention impact adherence to the treatment of latent tuberculous infection? Int J Tuberc Lung Dis, 2013,17(9):1178-1185. doi: 10.5588/ijtld.12.0823.
URL
pmid: 23928167
|
[14] |
Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018.
doi: 10.1183/13993003.01470-2018
URL
pmid: 30361241
|
[15] |
Sterling TR, Moro RN, Borisov AS, et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis, 2015,61(4):527-535. doi: 10.1093/cid/civ323.
doi: 10.1093/cid/civ323
URL
pmid: 25904367
|
[16] |
Jo KW, Kim JS, Kwon HS, et al. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers. Respir Med, 2019,158:42-48. doi: 10.1016/j.rmed.2019.10.005.
URL
pmid: 31605920
|
[17] |
Sentís A, Vasconcelos P, Machado RS, et al. Failure to complete treatment for latent tuberculosis infection in Portugal, 2013—2017: geographic-, sociodemographic-, and medical-associated factors. Eur J Clin Microbiol Infect Dis, 2020,39(4):647-656. doi: 10.1007/s10096-019-03765-y.
doi: 10.1007/s10096-019-03765-y
URL
pmid: 31797155
|
[18] |
Plourde PJ, Basham CA, Derksen S, et al. Latent tuberculosis treatment completion rates from prescription drug administrative data. Can J Public Health, 2019,110(6):705-713. doi: 10.17269/s41997-019-00240-1.
doi: 10.17269/s41997-019-00240-1
URL
pmid: 31297736
|
[19] |
Bennett RJ, Brodine S, Waalen J, et al. Prevalence and treatment of latent tuberculosis infection among newly arrived refugees in San Diego County, January 2010-October 2012. Am J Public Health, 2014,104(4):e95-e102. doi: 10.2105/AJPH.2013.301637.
URL
pmid: 24524534
|
[20] |
Eastment MC, McClintock AH, McKinney CM, et al. Factors That Influence Treatment Completion for Latent Tuberculosis Infection. J Am Board Fam Med, 2017,30(4):520-527. doi: 10.3122/jabfm.2017.04.170070.
doi: 10.3122/jabfm.2017.04.170070
URL
pmid: 28720633
|
[21] |
谷战英, 孙强, 姚静静. 定点医院模式实施前后结核病控制效果分析. 中国公共卫生, 2017,33(1):84-87. doi: 10.11847/zgggws2017-33-01-21.
|